Pharma Focus Asia

Chipscreen's New CS32582 Capsules Granted Clinical Approval for Psoriasis Treatment

Friday, November 03, 2023

Shenzhen Chipscreen Biosciences Co., Ltd., with stock code 688321.SH, has received approval from the National Medical Products Administration (NMPA) for clinical trials of CS32582 capsules to treat psoriasis through its subsidiary, Chengdu Chipscreen Pharmaceutical Co., Ltd.

CS32582 is a novel small molecule developed by Chipscreen, specifically targeting Tyrosine Kinase 2 (TYK2) through its allosteric inhibition. It binds to the regulatory pseudokinase JH2 domain of TYK2, ensuring selective inhibition without affecting other family members like JAK1, JAK2, and JAK3 at therapeutic doses. This unique feature ensures both therapeutic efficacy and safety.

CS32582 effectively inhibits TYK2, which in turn blocks signaling pathways mediated by cytokines such as interleukin (IL)-23, IL-12, and interferon (IFN) type I. This mechanism contributes to its potential in treating autoimmune diseases like psoriasis, as demonstrated in preclinical studies in mouse models.

Psoriasis is a chronic, immune-mediated, inflammatory condition influenced by both genetics and the environment. It is associated with various comorbidities, including psoriatic arthritis, cardiovascular disease, metabolic syndrome, obesity, diabetes, inflammatory bowel disease, and depression, affecting patients' quality of life.

Conventional systemic oral therapies are non-targeted, often leading to unwanted side effects and long-term safety concerns. Therefore, there is a pressing need for safer and more effective targeted oral therapies.

Small molecule targeted oral medications, such as the TYK2 inhibitor Deucravacitinib tablet, have shown superior efficacy and safety compared to traditional systemic treatments.

CS32582 holds potential as a promising therapeutic option for autoimmune diseases like psoriasis, where cytokines like IL-23, IL-12, and type I IFN play a significant role. It is expected to offer patients a more effective and safer treatment alternative compared to existing clinical medications.

 

Source: prnasia.com

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024